Brii Biosciences Reports Major Developments and 2025 Financial Results Brii Biosciences has released its 2025 financial results and updates on its HBV treatment strategies, showcasing advancements in drug development and discovery.

Brii Biosciences Reports Major Developments and 2025 Financial Results #USA #Durham #Brii_Biosciences #HBV_Treatment #biotech_company

Brii Biosciences Partners with OpenBench for AI-Enhanced Discovery Platform Brii Biosciences teams up with OpenBench to leverage AI technology for accelerating drug discovery efforts and addressing diseases with unmet needs.

Brii Biosciences Partners with OpenBench for AI-Enhanced Discovery Platform #United_States #AI_Technology #Durham #Brii_Biosciences #OpenBench

Brii Biosciences Showcases Promising Phase 2 ENSURE Study Data at AASLD 2025 Brii Biosciences reveals groundbreaking data from the Phase 2 ENSURE study, highlighting the potential of BRII-179 in curing chronic Hepatitis B at AASLD 2025.

Brii Biosciences Showcases Promising Phase 2 ENSURE Study Data at AASLD 2025 #USA #Washington_D.C. #Hepatitis_B #BRII-179 #Brii_Biosciences

Brii Biosciences Unveils Encouraging Phase 2 ENSURE Study Results for Hepatitis B Brii Biosciences has published promising results from its Phase 2 ENSURE study in Nature Medicine, showcasing significant advancements in hepatitis B treatment.

Brii Biosciences Unveils Encouraging Phase 2 ENSURE Study Results for Hepatitis B #USA #Durham,_NC #BRII-179 #Brii_Biosciences #elebsiran

Brii Biosciences and Joincare Group Forge Strategic Licensing Deal for BRII-693 in Greater China Market Brii Biosciences Limited has signed a licensing and technology transfer agreement with Joincare Group to develop BRII-693 in Greater China.

Brii Biosciences and Joincare Group Forge Strategic Licensing Deal for BRII-693 in Greater China Market #China #Beijing #Brii_Biosciences #Joincare_Group #BRII-693

Brii Biosciences Unveils Promising Data on BRII-179 in Phase 2 ENSURE Study at APASL 2025 Brii Biosciences Limited presented exciting findings at APASL 2025, indicating BRII-179's potential to enhance HBsAg loss in chronic HBV patients, paving the way for future treatments.

Brii Biosciences Unveils Promising Data on BRII-179 in Phase 2 ENSURE Study at APASL 2025 #BRII-179 #Brii_Biosciences #ENSURE_Study

Brii Biosciences Shares Strategic Insights and Full-Year 2024 Results Explore Brii Biosciences' impactful updates on its HBV treatment strategies and the financial outcomes for the year 2024, including significant clinical advancements.

Brii Biosciences Shares Strategic Insights and Full-Year 2024 Results #USA #Durham #BRII-179 #Brii_Biosciences #HBV_Treatment